相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways
Jan Philipp Bewersdorf et al.
BLOOD REVIEWS (2021)
Under-use of Hypomethylating Agents in Patients With Higher-risk Myelodysplastic Syndrome in the United States: A Large Population-based Analysis
Shelby Corman et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies
Ken Ogasawara et al.
CLINICAL PHARMACOKINETICS (2020)
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†
Amy J. Davidoff et al.
LEUKEMIA & LYMPHOMA (2020)
Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?
Esten N. Vandsemb et al.
CANCER (2019)
Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled
Jan Philipp Bewersdorf et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Yuxin Liu et al.
BLOOD REVIEWS (2019)
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Amer M. Zeidan et al.
CLINICAL CANCER RESEARCH (2018)
Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States
Amer M. Zeidan et al.
LEUKEMIA & LYMPHOMA (2017)
DNA Hypomethylating Drugs in Cancer Therapy
Takahiro Sato et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
A Call for Action: Increasing Enrollment of Untreated Patients With Higher-Risk Myelodysplastic Syndromes in First-Line Clinical Trials
Amer M. Zeidan et al.
CANCER (2017)
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
A. M. Zeidan et al.
LEUKEMIA (2016)
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Amer M. Zeidan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML
Monique Dail et al.
BLOOD (2016)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Huili Li et al.
ONCOTARGET (2014)
Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses
Li-Xin Wang et al.
PLOS ONE (2013)
Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells
Ben Youngblood et al.
IMMUNITY (2011)
Epigenetic Mechanisms of Promigratory Chemokine CXCL14 Regulation in Human Prostate Cancer Cells
Eun Young Song et al.
CANCER RESEARCH (2010)
Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
Jacqueline D. Shields et al.
SCIENCE (2010)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma:: Immunotherapeutic implications
Ester Fonsatti et al.
CLINICAL CANCER RESEARCH (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model
ZS Guo et al.
CANCER RESEARCH (2006)
分享论文
